| ²é¿´: 675 | »Ø¸´: 2 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
ai532521ľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ҩѧ·Ò룬лл
|
|
|
Two structurally interesting new norlignans named 2-hydroxy-4-[4-hydroxyphenyl-(4-hydroxy-3- methoxybenzyl)]-3-(3,5-dihydroxyphenyl)tetrahydrofuran (pouzolignan A), and 1,4-dihydroxy-3- [4-hydroxyphenyl-(4-hydroxy-3-methoxybenzyl)]-2-(3,5-dihydroxyphenyl)butane ÎÒÏëÎÊÒ»ÏÂÔÚÕâ¸ö¾ä×ÓÖÐinteresting·Òë³Éʲô»á±È½ÏºÃ |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸»ª¶«Ê¦·¶ÉúÎïѧ326·Ö£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
071000ÉúÎïѧµ÷¼ÁÇóÖú
ÒѾÓÐ11È˻ظ´
»¯Ñ§¹¤³ÌÓë¼¼Êõ324µ÷¼Á
ÒѾÓÐ16È˻ظ´
298Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
282£¬Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ19È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
ÖпÆÔº×Ü·Ö315Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á ²ÄÁÏÓ빤³Ì 324·Ö ר˶
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸¿ó´ó£¬²ÄÁϹ¤³Ìר˶314·Ö£¬0856¿Éµ÷¶¼¿ÉÒÔ
ÒѾÓÐ12È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÒ©¼ÁרҵµÄʦÐÖʦ½ã½øÀ´°ï¸ö档лл´ó¼Ò¡£
ÒѾÓÐ7È˻ظ´
°ïæ·ÒëÕâ¾ä»°
ÒѾÓÐ11È˻ظ´
ҩѧ·Ò룬лл
ÒѾÓÐ8È˻ظ´
ÇóÖú·ÒëÒ»¾ä»°
ÒѾÓÐ5È˻ظ´
ҩѧ·Ò룬лл
ÒѾÓÐ9È˻ظ´
ҩѧ·Ò룬лл
ÒѾÓÐ2È˻ظ´
ÇóÖú£¬Ò©Ñ§·Òë
ÒѾÓÐ3È˻ظ´
¶¼À´ËµÒ»ËµÒ½Ñ§ºÍҩѧ·ÒëÈí¼þ
ÒѾÓÐ8È˻ظ´
Çó°ïæ·Òëһϣ¬ºÃ¶àרҵÊõÓï¿´²»¶®
ÒѾÓÐ4È˻ظ´
4¸ö³£ÓõÄҩѧÈí¼þ
ÒѾÓÐ77È˻ظ´
splenotropic agentsÔõô·Òë
ÒѾÓÐ5È˻ظ´
ÇóҩѧÏà¹ØÖÐÎÄÂÛÎĵÄÓ¢Óï·Òë
ÒѾÓÐ6È˻ظ´
ҩѧרҵӢÓ¡ª¡¶Pharmaceutical English¡·½Ì°¸
ÒѾÓÐ373È˻ظ´
ÔÚÒ©ÎﻯѧÖÐ PK profile Ôõô·Òë ÊÇʲôÒâ˼°¡
ÒѾÓÐ11È˻ظ´
»¯Ñ§ºÏ³É²½Ö裬·Òë¹ýÁ˲»ÊÇÌ«Ã÷°×£¡¼±ÇóÖú
ÒѾÓÐ5È˻ظ´
Çó¡°Âí¶ûÎÄÁ£¶ÈÒǵÄÒÇÆ÷²ÎÊý·Ò롱£¬Çë´ó¼Ò°ïÖúÁË£¡
ÒѾÓÐ6È˻ظ´
·ÒëFDA×¢²áÍâÎÄÊ飬ÎÒÃÇÒ»ÆðŬÁ¦°É£¡
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿ÇóÖú×îÐÂÁ÷ÐкÃÓõķÒë´Êµä£¬Èçбàȫҽҩѧ´ó´Êµä£¬Ð»Ð»£¡
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿Ò©Îﻯѧרҵ¸´ÊÔʱ£¬×¨ÒµÓ¢Óï·ÒëÔõô°ì
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿ÓÐÄÄЩ±È½ÏºÃµÄ·Òë¾ä×ÓÈí¼þ¡£
ÒѾÓÐ7È˻ظ´
greenhand_ku
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 57 (³õÖÐÉú)
- ¹ó±ö: 0.087
- ½ð±Ò: 1735.9
- É¢½ð: 1226
- ºì»¨: 23
- ɳ·¢: 1
- Ìû×Ó: 619
- ÔÚÏß: 258Сʱ
- ³æºÅ: 2120375
- ×¢²á: 2012-11-08
- ÐÔ±ð: GG
- רҵ: Óлú¸ß·Ö×Ó²ÄÁÏ

3Â¥2013-11-27 12:50:21
befair
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 131 (¸ßÖÐÉú)
- ½ð±Ò: 12335.3
- ºì»¨: 20
- Ìû×Ó: 661
- ÔÚÏß: 608.6Сʱ
- ³æºÅ: 2651461
- ×¢²á: 2013-09-13
- ÐÔ±ð: GG
- רҵ: ºê¹Û¾¼Ã¹ÜÀíÓëÕ½ÂÔ

2Â¥2013-11-25 08:09:58













»Ø¸´´ËÂ¥